The present disclosure discloses an anti-Claudin 6 antibody and an antibody-drug conjugate. The present disclosure relates to an antigen sequence for preparing the Claudin 6 (CLDN6) antibody, a corresponding nucleotide sequence thereof, and a gene engineering vector, engineering bacterium or cell line for expressing the nucleotide sequence. A highly specific CLDN6 antibody may be produced by immunizing an animal with the antigenic polypeptide. Further, a corresponding monoclonal antibody may be obtained by preparing a hybridoma cell with a cell of the immunized animal. The anti-Claudin 6 antibody may be combined with a linking structure and a drug to form an antibody-drug conjugate. The antibody-drug conjugate may deliver the drug to a tumor cell having a positive expression of CLDN6 depending on the targeting effect of the CLDN6, thereby achieving the efficacy of specifically killing the tumor cell, which is of great significance for the treatment of the tumor.

The present disclosure discloses an anti-Claudin 6 antibody and an antibody-drug conjugate. The present disclosure relates to an antigen sequence for preparing the Claudin 6 (CLDN6) antibody, a corresponding nucleotide sequence thereof, and a gene engineering vector, engineering bacterium or cell line for expressing the nucleotide sequence. A highly specific CLDN6 antibody may be produced by immunizing an animal with the antigenic polypeptide. Further, a corresponding monoclonal antibody may be obtained by preparing a hybridoma cell with a cell of the immunized animal. The anti-Claudin 6 antibody may be combined with a linking structure and a drug to form an antibody-drug conjugate. The antibody-drug conjugate may deliver the drug to a tumor cell having a positive expression of CLDN6 depending on the targeting effect of the CLDN6, thereby achieving the efficacy of specifically killing the tumor cell, which is of great significance for the treatment of the tumor.

The present disclosure provides a ready-to-use liquid formulation comprising bupivacaine hydrochloride, dexamethasone sodium phosphate and epinephrine (collectively referred to as Bupivisone Plus), and methods for preparing, packaging, storing and using the same.

The present disclosure provides a ready-to-use liquid formulation comprising bupivacaine hydrochloride, dexamethasone sodium phosphate and epinephrine (collectively referred to as Bupivisone Plus), and methods for preparing, packaging, storing and using the same.

MPO1 and MPO2 can be regulated for either decreasing or increasing alkaloid levels in plants, in particular in Nicotiana plants. In particular, suppressing or overexpressing one or more of MPO1 and MPO2 may be used to decrease or increase nicotine and nicotinic alkaloid levels in tobacco plants. Suppression or overexpression of one or more of MPO1 and MPO2 may be used in combination with modification of expression of other genes encoding enzymes on the nicotinic alkaloid biosynthetic pathway such as A622, NBB1, PMT, and QPT.

MPO1 and MPO2 can be regulated for either decreasing or increasing alkaloid levels in plants, in particular in Nicotiana plants. In particular, suppressing or overexpressing one or more of MPO1 and MPO2 may be used to decrease or increase nicotine and nicotinic alkaloid levels in tobacco plants. Suppression or overexpression of one or more of MPO1 and MPO2 may be used in combination with modification of expression of other genes encoding enzymes on the nicotinic alkaloid biosynthetic pathway such as A622, NBB1, PMT, and QPT.

The present invention provides a composition, preferably a dietary or pharmaceutical composition, comprising or consisting of vitamin(s) (a), and optionally minerals (b), and a pharmaceutically or dietetically suitable carrier such as nutrients DHA and/or EPA (c), encapsulated in a soft gelatine such as a bovine, porcine, vegetable and succinylated gelatine shell, wherein the vitamin(s) include Vitamin C and said Vitamin C is, at least in part, in the form of an ascorbate salt such as, but not limited to, Calcium ascorbate or any other divalent cation salt such as Magnesium ascorbate.

The present invention provides a composition, preferably a dietary or pharmaceutical composition, comprising or consisting of vitamin(s) (a), and optionally minerals (b), and a pharmaceutically or dietetically suitable carrier such as nutrients DHA and/or EPA (c), encapsulated in a soft gelatine such as a bovine, porcine, vegetable and succinylated gelatine shell, wherein the vitamin(s) include Vitamin C and said Vitamin C is, at least in part, in the form of an ascorbate salt such as, but not limited to, Calcium ascorbate or any other divalent cation salt such as Magnesium ascorbate.

The present invention relates to compositions, in particular dietary compositions, that comprise a combination of choline cation and succinate anion (2−) and nicotinamide, and use of these compositions for maintaining and enhancing the brain energy metabolism in a human, and for preventing and treating symptoms and physiological conditions associated with an imbalanced, damaged or slowed brain energy metabolism in a human subject.

The present invention relates to compositions, in particular dietary compositions, that comprise a combination of choline cation and succinate anion (2−) and nicotinamide, and use of these compositions for maintaining and enhancing the brain energy metabolism in a human, and for preventing and treating symptoms and physiological conditions associated with an imbalanced, damaged or slowed brain energy metabolism in a human subject.